Related Experiment Video
Updated: Mar 7, 2026
12:19
Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS
Published on: October 7, 2009
27.8K
The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on
V J J Schettler1, C L Neumann2, C Peter3,4
1Center of Nephrology Göttingen GbR, An der Lutter 24, 37075, Göttingen, Germany. v.schettler@nz-goe.de.
Clinical Research in Cardiology Supplements
|February 25, 2017
Summary
Lipoprotein apheresis (LA) significantly reduces cardiovascular events in patients with high LDL-C or Lp(a) levels. This safe treatment demonstrated a 78% reduction in major adverse cardiovascular events over two years.
Area of Science:
- Cardiology
- Lipidology
- Public Health
Background:
- Established in 2005, the German Lipoprotein Apheresis Registry (GLAR) collects data on apheresis treatments.
- Data collection followed current guidelines and the German indication guideline for apheresis (2009).
Purpose of the Study:
- To evaluate the effectiveness and safety of lipoprotein apheresis (LA) in patients with high LDL-C and/or Lp(a) levels.
- To assess the impact of LA on cardiovascular event rates and treatment-related side effects.
Main Methods:
- Retrospective and prospective observational data from 1435 patients across 71 German apheresis centers (2012-2016).
- Analysis of 15,527 LA treatments, focusing on LDL-C and Lp(a) reduction rates.
- Comparison of major adverse cardiovascular events (MACE) incidence one and two years before LA and two years after LA initiation.
Main Results:
- Median LDL-C reduction of 67.5% and Lp(a) reduction of 71.1% was observed.
- A significant 78% reduction in MACE was recorded during two years of LA treatment.
- Side effects were low (5.9%), primarily related to puncture site issues.
Conclusions:
- Lipoprotein apheresis (LA) effectively lowers cardiovascular event incidence in high-risk patients.
- LA is a safe therapeutic option for patients with progressive cardiovascular disease and maximally tolerated lipid-lowering medication.
